www.nextgensciences.com
NextGen Achieve Commercial Milestone With the Launch of Gene Synthesis Services NextGen Sciences, the Cambridge, UK based “Gene to Protein” company today announced they had achieved one of the milestones in the agreement with Gene Oracle with the launch of a new service for Gene Synthesis. This launch represents a further addition to the suite of services it already offers through its ContractExpressTM fee for service business using the proprietary technology developed by Gene Oracle. The GeneIOSTM technology provides significant performance and time saving benefits when compared with competing technologies. Customers will also have the option to combine Gene Synthesis with other complementary services provided under the ContractExpress offering, such as cloning and expression through to protein identification, characterization and manufacture. NextGen Sciences believe the new combined ContractExpress Gene Synthesis module offers customers a very cost effective service, including full design consultation and guaranteed sequence verification, that can deliver purified samples to the customer within 10 working days from agreeing a contract. Commenting on the launch of the service, CEO Dr James Heffernan said: ”From the date of the announcement of the agreement with Gene Oracle it has taken us less than 2 months to incorporate the Gene Oracle algorithms into the Company’s existing infrastructure. This has allowed us to expand the scope of our fee for service business on schedule and represents a significant milestone achieved by NextGen in the expansion of the ContractExpressTM fee for service business. The way we have identified, negotiated access to and incorporated best of breed technologies into our own suite of products is indicative of the way NextGen is positioning itself to be at the heart of supporting the drug discovery industry.” This product launch represents a significant milestone in the agreement with Gene Oracle announced in August 2006, which entitled NextGen to in-licence Gene Oracle’s proprietary gene synthesis technology, and also to a time limited exclusive option to acquire Gene Oracle at a later date Further information on Gene Synthesis or ContractExpress can be obtained from the NextGen website www.nextgensciences.com or from the Contract Services Manager Dr Barry McAleer on +44 (0) 1480 410 850, barry.mcaleer@nextgensciences.com. -ends- For further details please contact: Dr James G Heffernan CEO, NextGen Group PLC 01480 420 979 Mike Wort, Anna Dunphy MC Bio-Communications Limited 020 7744 7711 Notes to Editors: About NextGen Sciences NextGen Group PLC (LSE:NGG) floated on the AIM market in London in December 2005 raising £1.9 million in an oversubscribed offering which included strong institutional investor support from Germany as well as in the UK. The Agreement with Gene Oracle Inc. follows on from the successful commercial alliance formed with Proteomic Research Services Inc. of Michigan, USA which was announced in January and considerably widened the scope of services that NextGen could supply to its customer base. Further details relating to NextGen Group PLC and its products can be found at www.nextgensciences.com
If you can’t open this electronic message, visit www.nextgensciences.com
about us>
© NextGen Sciences Ltd 2006, All rights reserved If this information is not of interest to you, and you no longer wish to receive press releases, we apologise for any inconvenience caused. To be removed from further emails please click here